新产业（300832）公告，2024年营业收入为45.35亿元，同比增长15.41%。归属于上市公司股东的净利 润18.28亿元，同比增长10.57%。基本每股收益2.33元/股，同比增长10.53%。公司拟向全体股东每10股 派发现金红利13元(含税)。 ...

Financial Performance - The company's operating revenue for 2024 reached ¥4,535,404,459.13, representing a 15.41% increase compared to ¥3,929,655,726.27 in 2023[15]. - The net profit attributable to shareholders for 2024 was ¥1,828,456,618.27, up 10.57% from ¥1,653,653,244.98 in 2023[15]. - The net profit after deducting non-recurring gains and losses was ¥1,720,490,659.23, an increase of 11.19% from ¥1,547,315,497.48 in 2023[15]. - The total assets at the end of 2024 amounted to ¥9,619,453,527.11, reflecting a 16.99% growth from ¥8,222,488,843.69 at the end of 2023[15]. - The net assets attributable to shareholders increased by 13.68% to ¥8,576,607,474.91 at the end of 2024, compared to ¥7,544,400,237.20 at the end of 2023[15]. - The company reported a decrease in cash flow from operating activities, with a net cash flow of ¥1,356,439,053.53, down 4.36% from ¥1,418,292,417.91 in 2023[15]. - The company reported a basic earnings per share of ¥2.3271 for 2024, a 10.53% increase from ¥2.1054 in 2023[15]. - The overall revenue for the reporting period reached 4.535 billion yuan, a growth of 15.41% compared to the previous year[56]. - The gross profit margin for the company was 72.26%, with the instrument gross profit margin increasing to 29.82%[56]. - The company's overseas business achieved a main operating income of 1.684 billion yuan, a year-on-year increase of 27.67%[54]. Market and Industry Insights - The global in vitro diagnostic market is projected to reach $109.2 billion in 2024, with a compound annual growth rate of 4.3% from 2024 to 2029[24]. - The Chinese in vitro diagnostic market size was approximately ¥998.13 billion in 2023, driven by policy support and increasing market demand[26]. - The domestic in vitro diagnostic market is experiencing rapid growth due to the shift in medical consumption concepts and the aging population, with significant potential for market expansion[128]. - The domestic immunodiagnostics market reached 37.52 billion RMB in 2023, accounting for 37.59% of the total in vitro diagnostics market, with multinational companies holding 71.2% market share[27]. - The immunodiagnostics market experienced a growth rate of 13% in 2023, driven by a rebound in diagnostic volumes and the recovery of routine testing demand[27]. - The domestic biochemical diagnostics market was valued at 11.15 billion RMB in 2023, with a year-on-year growth of 5%, and local manufacturers increasing their procurement ratio in hospitals[27]. Product Development and Innovation - The company has developed 224 types of chemical luminescence immunoassays, with 198 having obtained EU market access, making it one of the most comprehensive suppliers in the industry[32]. - The company launched the high-throughput MAGLUMI X10 in early 2024, enhancing efficiency for medical terminals[149]. - The company has established four major technology platforms for in vitro diagnostic product development, including nano magnetic microspheres, key reagent raw materials, fully automated diagnostic instruments, and diagnostic reagents[38]. - The company has developed innovative products such as the Molecision R8 and MAGLUMI X10, which feature high throughput and advanced contamination prevention technologies[67][68]. - The company is focusing on product line strategic planning and enhancing project reliability and compliance in instrument development[66]. Corporate Governance and Investor Relations - The company has established a governance structure that includes a board of directors, supervisory board, and management team, ensuring compliance with relevant laws and regulations[154]. - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with governance standards[157]. - The company emphasizes independent operations, with no interference from the controlling shareholder in decision-making or business activities[156]. - The company has a performance evaluation and incentive mechanism for senior management directly linked to operational performance, overseen by the remuneration and assessment committee[160]. - The company actively engages with stakeholders to balance interests and promote sustainable development[161]. - The company is committed to transparency and regular communication with investors, as evidenced by its detailed activity records shared on the 巨潮资讯网 platform[142][143]. Risk Management - The company has a comprehensive risk management strategy outlined in the report, detailing potential risks and countermeasures[3]. - The company has established a comprehensive risk management framework for its foreign exchange hedging activities to mitigate potential risks[121]. - The company is aware of the risks associated with new product development, including potential delays and regulatory challenges, and is enhancing its pre-research and market analysis efforts[134][135]. Employee and Management Insights - The total number of employees at the end of the reporting period is 2,841, including 2,816 from the parent company and 25 from major subsidiaries[200]. - The company has 898 production personnel, 545 sales personnel, 348 technical personnel, and 836 R&D personnel, indicating a strong focus on research and development[200]. - The educational background of employees includes 9 with PhDs, 552 with master's degrees, and 1,499 with bachelor's degrees, reflecting a highly educated workforce[200]. Cash Dividend and Shareholder Returns - The company plans to distribute a cash dividend of 13 RMB for every 10 shares, totaling approximately 1,021,434,420.50 RMB, which represents 55.86% of the net profit attributable to shareholders for the year 2024[152]. - The company has maintained a dividend payout ratio above 40% for five consecutive years from 2020 to 2024, positioning it in the upper tier of the A-share market[152]. - The company actively promotes cash dividends to enhance shareholder returns as part of its "Quality Return Dual Improvement" action plan[148].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 1,124,761,573, representing a 10.12% increase compared to CNY 1,021,430,175 in the same period last year[4] - Net profit attributable to shareholders was CNY 437,511,949, a 2.65% increase from CNY 426,221,044 in the previous year[4] - The net profit after deducting non-recurring gains and losses was CNY 416,658,656, up 4.39% from CNY 399,135,667 in the same period last year[4] - The company's weighted average return on equity decreased by 0.52 percentage points to 4.97% from 5.49% in the previous year[4] - The company achieved operating revenue of RMB 1,124.76 million, representing a year-on-year growth of 10.12%[17] - Domestic main business revenue grew by 0.11% year-on-year, while overseas main business revenue increased by 27.03%[17] - Total operating revenue for the current period reached ¥1,124,761,573, an increase of 10.1% compared to ¥1,021,430,174.73 in the previous period[23] - Net profit for the current period was ¥437,511,949.25, reflecting a slight increase of 2.9% from ¥426,221,043.84 in the previous period[24] - Basic and diluted earnings per share improved to ¥0.5568, compared to ¥0.5425 in the prior period[25] Cash Flow and Liquidity - The company's cash flow from operating activities showed a significant decline, with a net cash flow of CNY 18,542,686, down 92.92% from CNY 261,740,278 in the previous year[10] - Cash flow from operating activities saw a significant decline due to a delay in accounts payable payments, which will be concentrated in January 2025[17] - The company's cash and cash equivalents decreased to RMB 651.09 million from RMB 919.53 million[18] - The net cash flow from operating activities was $18,542,685.84, a significant decrease of 92.9% compared to $261,740,277.69 in the previous period[26] - Cash outflow from operating activities totaled $987,541,010.85, up 42.6% from $692,205,163.45 in the prior period[26] - The ending balance of cash and cash equivalents was $651,087,913.23, down 36.6% from $1,027,068,268.06 at the end of the previous period[26] Assets and Liabilities - Total assets at the end of the reporting period were CNY 9,729,267,086, reflecting a 1.14% increase from CNY 9,619,453,527 at the end of the previous year[4] - The equity attributable to shareholders increased by 4.98% to CNY 9,003,866,643 from CNY 8,576,607,475 at the end of the previous year[4] - Total liabilities decreased to ¥725,400,442.96 from ¥1,042,846,052.20, indicating a reduction of approximately 30.4%[21] - The total liabilities and equity amounted to ¥9,729,267,085.68, up from ¥9,619,453,527.11, reflecting a growth of 1.1%[21] Operating Costs and Profitability - The company's gross profit margin decreased, with operating costs rising by 34.61% to CNY 359,759,645 due to increased sales volume of large instruments[9] - Total operating costs amounted to ¥643,259,211.97, up 15.1% from ¥558,596,850.28 in the prior period, with operating costs specifically rising from ¥267,255,498.99 to ¥359,759,644.98[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 19,269[12] Government Support - The company received government subsidies amounting to CNY 15,265,086, a 125.88% increase compared to CNY 6,758,014 in the previous year[9] Research and Development - Research and development expenses remained stable at ¥101,897,244.82, slightly increasing from ¥101,455,514.48[24] Other Financial Activities - The company reported a significant increase in its debt investment, rising to RMB 1,868.42 million from RMB 1,778.96 million[19] - The company plans to upgrade its ERP system by the end of 2024, which may impact payment processes[17] - Other comprehensive income after tax decreased to -¥10,252,781.44 from -¥6,112,114.04, indicating a decline in this area[24] - The net cash flow from investing activities was -$295,543,409.68, worsening from -$277,676,044.43 in the previous period[26] - The total cash outflow from investing activities was $1,032,671,858.93, a decrease of 45.4% from $1,887,962,302.77[26] Audit Information - The company did not undergo an audit for the first quarter report[28]

深圳市新产业生物医学工程股份有限公司 内部控制审计报告 政旦志远内字第 2500008 号 政旦志远(深圳)会计师事务所(特殊普通合伙) Zandar Certified Public Accountants LLP 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）_ 报告编 深圳市新产业生物医学工程股份有限公司 内部控制审计报告 (截止 2024 年 12 月 31 日） 页 次 录 一、 1-2 ZANDAR | 政旦去途 内 部 控 制 审 计 报 告 政旦志远内字第 2500008 号 深圳市新产业生物医学工程股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求,我们审计了深圳市新产业生物医学工程股份有限公司(以下 简称新产业公司)2024年12月31日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 业内部控制评价指引》的规定,建立健全和有效实施内部控制,并评 价其有效性是企业董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基 ...

深圳市新产业生物医学工程股份有限公司 控股股东及其他关联方资金占用情况的专项说明 （截止 2024 年 12 月 31 日） 深圳市新产业生物医学工程股份有限公司 控股股东及其他关联方资金占用情况的 专项说明 政旦志远核字第 2500042 号 政旦志远（深圳）会计师事务所（特殊普通合伙） Zandar Certified Public Accountants LLP 目 录 页 次 一、 控股股东及其他关联方资金占用情况的专项 说明 1-2 二、 深圳市新产业生物医学工程股份有限公司 2024 年度非经营性资金占用及其他关联资金 往来情况汇总表 1 地 址：深圳市福田区鹏程一路广电金融中心 11F 电 话：+86-755-88605026 www.zdcpa.com 控 股 股 东 及 其 他 关 联 方 资 金 占 用 情 况 的 专 项 说 明 政旦志远核字第 2500042 号 深圳市新产业生物医学工程股份有限公司全体股东： 我们接受委托，依据《中国注册会计师执业准则》审计了深圳市 新产业生物医学工程股份有限公司（以下简称新产业公司）2024 年度 财务报表，包括 2024 年 12 月 31 日的合 ...

深圳市新产业生物医学工程股份有限公司 深圳市新产业生物医学工程股份有限公司 审计报告及财务报表 （2024 年 1 月 1 日至 2024 年 12 月 31 日止） | | | 目 录 | 页 次 | | --- | --- | --- | --- | | 一、 | 审计报告 | | 1-8 | | 二、 | 已审财务报表 | | | | | 合并资产负债表 | | 1-2 | | | 合并利润表 | | 3 | | | 合并现金流量表 | | 4 | | | 合并股东权益变动表 | | 5-6 | | | 母公司资产负债表 | | 7-8 | | | 母公司利润表 | | 9 | | | 母公司现金流量表 | | 10 | | | 母公司股东权益变动表 | | 11-12 | | | 财务报表附注 | | 1-101 | 地 址：深圳市福田区鹏程一路广电金融中心11F 电 话：+86-755-88605026 www.zdcpa.com 审计报告 政旦志远审字第 2500096 号 政旦志远（深圳）会计师事务所（特殊普通合伙） Zandar Certified Public Accountants LLP ...

4月25日，广东省属国资国企高质量发展新闻发布会在广州召开。会上，广东省国资委、广东省科技厅、广晟控股集团、广新控 股集团介绍了省属国资国企高质量发展的具体举措和成效。 （发布会现场） 2024年，省属企业资产总额2.73万亿元、较2020年增长37.8%，实现营业收入7,022.05亿元、利润总额387.83亿元、增加值 1,600.28亿元，较2020年分别增长57.8%、57.2%、41.8%；2025年一季度，省属企业实现营业收入1,618.67亿元、利润总额90.96 亿元、增加值395.25亿元，同比分别增长0.9%、9.5%、9.5%。 会上，广东省国资委以一组数据，亮出了广东国资国企践行高质量发展的最新"成绩单"，彰显国资国企在助力"稳经济"上的新 担当。 广东省国资委副主任王晓昀表示，近年来广东国企不断现代化产业体系向新提质，为高质量发展开拓新空间，为广东经济社会 持续稳定发展作出了积极贡献。 一方面，大力发展新兴产业，实施省属企业制造业投资五年倍增计划，更大力度布局制造业和战略性新兴产业，打造形成包括 广东先进制造业产业投资基金、战略性产业促进发展基金、上市公司高质量发展基金在内的先进制造 ...

北京青年报讯（记者 雷嘉）昨天，市政府新闻办召开2024年北京知识产权保护状况新闻发布会。 北京青年报记者了解到，去年以来，北京市持续加强对人工智能等战略性新兴产业、重点领域、关键核 心技术知识产权检察保护力度，办理了全市首例利用人工智能生成模型侵犯著作权犯罪案、全国首例 AI文生图著作权侵权案，探索护航人工智能产业创新发展的"北京实践"。 据介绍，2024年北京全市专利授权量19.9702万件，其中发明专利授权量11.9635万件。截至2024年 12月，全市有效发明专利量66.3490万件，同比增长15.52%。全市每万人口高价值发明专利拥有量 159.81件，稳居全国第一。世界知识产权组织发布的《2024年全球创新指数》中，北京排名全球科技集 群第三，较2023年上升一位。 去年北京市出台6项促进专利转化运用政策。认定建设北京市人工智能大模型、信息通信、生物制 品和能源装备智能化4个产业知识产权促进中心，推动重点产业知识产权强链增效。2024年北京认定登 记专利转让（含许可）合同2058项，成交额166.9亿元；全市专利开放许可声明2996件，居全国首位。 去年，市知识产权局、市财政局、国家金融监督管理 ...

南方财经全媒体记者 曹媛 深圳报道 大模型的出现引爆算力需求，但高昂的资金成本却令企业"望而却步"。 今年以来，随着国产大模型的升级，算力需求井喷。如在DeepSeek热潮带动下，国内大厂对H20芯片需 求旺盛。但硬件采购、算力租赁、后续运维等高昂的资金成本，却让中小企业"望而却步"。 为破解资金难题，近期全国多家银行密集推出"算力贷"产品。据南方财经全媒体记者不完全统计，截至 发稿前，今年已有至少5家银行推出"算力贷"相关信贷产品。 例如，2025年1月，兴业银行汕头分行落地汕头市首笔算力项目贷款，为某上市企业提供高达2.33亿元 项目贷款支持；3月中旬，交通银行青海省分行成功落地青海省内国有商业银行首笔绿色算力固定资产 贷款项目，一次性投放资金5560万元，专项支持青海省相关智算科技公司绿色算力设施建设及设备采 购。 再如，3月中旬，工商银行同福支行落地首个人工智能大模型企业千万元级算力贷款服务产品；3月底， 江苏银行上海分行与五家企业进行了"算力贷"首批银企合作客户签约，授信总金额达10亿元；近日顺德 农商银行也发放了一笔"算力贷"。 南方财经全媒体记者近期调研发现，上述银行推出的"算力贷"授信对象更聚 ...

航空制造业项目实现突破 全国飞机研发与制造头部企业入驻园区。一是钻石DA40飞机生产线正式启用。成功引进万丰集团，共同打造钻石DA40系列飞机生产供 应基地。对2.8万平方米的飞机制造厂房进行高标准改造提升，整机生产线全部安装调试到位，2024年12月，举行了生产线启用仪式，样 机已生产下线。二是打造全国新能源飞机研发试飞总装基地。成功招引中国商飞北研中心入驻园区，并于2024年8月与市政府签订战略合 作协议，把大高园区作为商飞新能源飞机研发试飞总装测试基地，引入相关资源，共同打造航空产业发展平台，120多人的研发团队常驻 园区进行研发攻关。 通航服务业项目集聚起势 一是大高国际航校正式承接山东航空学院飞行员培训。第一批学院的国航飞行员24人已入校培训，在校学员达65人，其中28名飞行员已 毕业上岗。二是航空研学独具特色。积极推动"大美滨州，逐梦蓝天"航空研学，年内被中国民航科普基金会授牌确定为中国民航科普教 育基地，年接待研学突破1.5万人次。三是航空俱乐部启动运行。创新设立航空俱乐部有限公司，积极打造商照培训、私照培训、通航飞 机维修培训以及空中游览体验等四大服务版块，截至2024年底发展会员300余名。 ...